4Z0X
Structure of Hepatitis C Virus Envelope glycoprotein E2 antigenic region 434-446 bound to the broadly neutralizing antibody HC26AM
4Z0X の概要
エントリーDOI | 10.2210/pdb4z0x/pdb |
分子名称 | Antibody HC26AM light chain variable domain, Antibody HC26AM heavy chain variable domain, HCV E2 Antigen (residues 432-446), ... (4 entities in total) |
機能のキーワード | hcv, broadly neutralizing antibody, immune system |
由来する生物種 | Homo sapiens 詳細 |
タンパク質・核酸の鎖数 | 3 |
化学式量合計 | 25641.42 |
構造登録者 | |
主引用文献 | Keck, Z.Y.,Wang, Y.,Lau, P.,Lund, G.,Rangarajan, S.,Fauvelle, C.,Liao, G.C.,Holtsberg, F.W.,Warfield, K.L.,Aman, M.J.,Pierce, B.G.,Fuerst, T.R.,Bailey, J.R.,Baumert, T.F.,Mariuzza, R.A.,Kneteman, N.M.,Foung, S.K. Affinity maturation of a broadly neutralizing human monoclonal antibody that prevents acute hepatitis C virus infection in mice. Hepatology, 64:1922-1933, 2016 Cited by PubMed Abstract: Direct-acting antivirals (DAAs) have led to a high cure rate in treated patients with chronic hepatitis C virus (HCV) infection, but this still leaves a large number of treatment failures secondary to the emergence of resistance-associated variants (RAVs). To increase the barrier to resistance, a complementary strategy is to use neutralizing human monoclonal antibodies (HMAbs) to prevent acute infection. However, earlier efforts with the selected antibodies led to RAVs in animal and clinical studies. Therefore, we identified an HMAb that is less likely to elicit RAVs for affinity maturation to increase potency and, more important, breadth of protection. Selected matured antibodies show improved affinity and neutralization against a panel of diverse HCV isolates. Structural and modeling studies reveal that the affinity-matured HMAb mediates virus neutralization, in part, by inducing conformational change to the targeted epitope, and that the maturated light chain is responsible for the improved affinity and breadth of protection. A matured HMAb protected humanized mice when challenged with an infectious HCV human serum inoculum for a prolonged period. However, a single mouse experienced breakthrough infection after 63 days when the serum HMAb concentration dropped by several logs; sequence analysis revealed no viral escape mutation. PubMed: 27641232DOI: 10.1002/hep.28850 主引用文献が同じPDBエントリー |
実験手法 | X-RAY DIFFRACTION (2 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード
